Inhaled corticosteroids versus long acting beta-agonists for chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Spencer, Sally ^a   Evans, D ^b  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLESONIDE; FLUTICASONE; FORMOTEROL; GLUCOCORTICOID; LONG ACTING DRUG; MOMETASONE FUROATE; SALMETEROL; TIOTROPIUM BROMIDE; TRIAMCINOLONE;

ADVERSE OUTCOME; CHRONIC OBSTRUCTIVE LUNG DISEASE; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; EMBASE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; LUNG FUNCTION TEST; MEDLINE; METHODOLOGY; MORTALITY; OUTCOME ASSESSMENT; QUALITY OF LIFE; REVIEW; SCORING SYSTEM;

EID: 44949090653     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007033     Document Type: Review

References (14)

1. Boyd 1997 Boyd G, Morice A, Pounsford J, Sibert M, Peslis N, Crawford C. An evaluation of Salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). European Respiratory Journal 1997;10: 815-21.
2. Burge 2000 Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial y of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
3. Calverley 2003 Calverley PMA, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56.
4. Calverley 2007 Calverley PM, Anderson JA, Bartolome C, Ferguson GT, Jenkins C, Jones PW, et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine 2007;356(8):775-89.
5. GOLD 2006 GOLD Executive Committee. GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. http: //www.goldcopd.com/ 2006.
6. Handbook 2005 Higgins JPT, Green S, editors. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] http://www.cochrane.org/resources/handbook/hbook.htm (accessed 25th January 2007). Chichester: John Wiley & Sons Ltd, 2005.
7. Jones 1997 Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. American Journal of Respiratory and Critical Care Medicine 1997;155:1283-9.
8. Lung Health 2000 The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New England Journal of Medicine 2000;343: 1902-9.
9. NICE 2004 National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(Suppl 1):1-232.
10. Pauwels 1999 Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al.Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. New England Journal of Medicine 1999;340 (25):1948-53.
11. Pauwels 2001 Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respiratory Care 2001;46(8):798-825.
12. Spencer 2001 Spencer S, Calverley PMA, Burge PS, Jones PW. Health status deterioration in patients with COPD. American Journal of Respiratory and Critical Care Medicine 2001;163:122-8.
13. Spencer 2003 Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003;58:589-93.
14. Vestbo 1999 Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. The Lancet 1999;353:1819-23.